BPC-157
Reviewed
Short answer
Cell and animal studies, plus small early studies in people, do not prove that BPC-157 heals injuries in people. Still being studied; no FDA-approved BPC-157 product identified.
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Read the study findingsAlso known as BPC 157 · Body Protection Compound 157 · pentadecapeptide BPC 157
Part of Healing and recovery peptides
Compared with TB-500
Sold in blends Wolverine · GLOW · KLOW
Legal status Is BPC-157 legal? See the status table
Study and product details
What it is
Online popularity is not proof that a treatment works. BPC-157 is a synthetic 15-amino-acid peptide promoted online for injury recovery and other uses. Popularity, testimonials, animal findings, and availability are not evidence of an approved or proven human treatment.
Type of peptide: Synthetic pentadecapeptide. This describes what the substance is or how it works. It does not show that it is safe, effective, or approved.
What has been studied?
- Limited: Research is too small or incomplete, or does not directly answer this question.
- Unclear: There is not enough reliable detail about the product or research to judge.
Small uncontrolled pilots cannot establish a patient benefit.
Human exposure and pharmacokinetic characterization remain sparse.
The human safety dataset is too small for confident risk estimates.
No validated approved formulation; identity and purity vary outside formal research.
Products with the same ingredient can differ.
The ingredient name does not tell you everything about a product. Check its other ingredients, its form, how it enters the body, and the use and people covered by the research or approval.
None identified in the United States.
- No FDA-approved indication
Have a lab test report (COA) for a product sold under this name? Check what the report shows in 10 questions
Not sure if a product sold under this name is a prescription, compounded, or research-only vial? Sort it in 5 questions
What studies found
The preclinical literature contains positive signals in cell and animal models, including tendon-healing models. Small human pilot work and registered clinical research now exist, but do not establish a clinical effect in people. FDA's July 2026 PCAC briefing evaluated BPC-157-related bulk substances for a nominated ulcerative-colitis use and documented evidence and safety gaps. That advisory-stage record supports scrutiny; it is not a final FDA determination.
The available evidence still does not establish that BPC-157 safely heals sports injuries or other conditions in people. Early, uncontrolled, or registered research is not the same as a replicated patient benefit, and a trial listing is not a positive result.
Which products do these findings apply to?
A peptide sequence, a nominated bulk substance, a clinical-study product, and a consumer vial are separate evidence objects. Identity and product quality cannot be assumed from the name.
BPC-157 side effects and safety: what FDA has said
This page has no trial or drug-label side-effect table for BPC-157. FDA keeps a page of bulk substances that may be risky when a pharmacy mixes (compounds) them. Here is what that page says about BPC-157, in plain words.
FDA's page does not name specific side effects for BPC-157.
- FDA found little or no safety information for the ways it was proposed to be given. It says it cannot tell whether BPC-157 would harm people.
- The body's immune system may react against it. FDA says this risk depends on how it is given.
- Making it may leave unwanted peptide by-products in the product.
- It may be hard to confirm exactly what the main ingredient is.
These points come from FDA's review of compounded drugs. They are not a full list of side effects. Having no reports does not mean a product is safe.
Read FDA's exact words
BPC-157: “Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.”
Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks , page dated .
Read the BPC-157 side effects guide
Compare side-effect data across peptides
Report a side effect
You can report a suspected side effect to the FDA at 1-800-FDA-1088 or through FDA MedWatch . If a reaction feels serious, get medical care first.
FDA page checked .
Fact checks
3 statements checked. Read what the results mean.
“BPC-157 improves tendon healing in preclinical models.”
Cell and rat tendon studies report positive healing signals. The scope matters: these results support biological plausibility, not a proven human treatment.
- What this answer is based on
- Cell, animal, or other lab research
- Limits of this answer
- Cell and animal tendon models only; not clinical healing outcomes in people.
Sources for this fact check (1)
“BPC-157 heals tendons and muscles in people.”
Early human work is too small and limited to establish efficacy. Reliable, replicated human outcome evidence is still needed.
- What this answer is based on
- No reliable studies showing this health result in people
- Limits of this answer
- Human tendon and muscle-healing claims; existing pilots and a trial registration do not establish benefit.
Sources for this fact check (3)
“Athletes can use it because it is not a steroid.”
The 2026 WADA Prohibited List places BPC-157 in S0 non-approved substances, which is prohibited at all times for covered athletes. Whether it is a steroid is irrelevant to that status.
- What this answer is based on
- Official record or product label
- Limits of this answer
- Athletes subject to the current WADA Code and their applicable governing-body rules.
Sources for this fact check (1)
Risks and safety limits
The site will not provide self-injection, reconstitution, dosing, sourcing, or stack instructions. “Research use only” does not establish quality or make a product appropriate for human use.
BPC-157 is listed under WADA's S0 non-approved substances category and is prohibited at all times for covered athletes.
Reviewed .Check the rules for athletes ↗Read the official rules ↗Terms used in the studies
- peptide
- a short chain of amino acids
- preclinical
- research in cells, tissues, or animals before or outside testing in people
- formulation
- the ingredients and physical form of the finished product
- outcome
- what the study measured
- amino acid
- a small building block that makes peptides and proteins
- investigational
- still being studied and not approved for that use
- indication
- the approved or studied use and patient group
Read the sources
Show 7 sources
Review history
Revalidated BPC-157's S0 prohibited-at-all-times status against the 2026 WADA Prohibited List.
Updated around FDA's July 2026 briefing and explicit product-identity boundaries.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.
Report a factual error